That's OncoIntelligenceTM.
Traditional tumor grading in breast cancer can be subjective, resulting in a high percentage of patients being classified with Intermediate/Grade 2 tumors even though many are low risk. As a result, patients must wait 2-6 weeks for costly gene expression test results, ultimately delaying vital care planning.
65%
Intra-observer variations in grading results***
56%
of Grade 3 tumors are low risk**
22%
of Grade 2 tumors are high risk**
78%
of Grade 2 tumors are low risk**
*Sparano, New England Journal of Medicine. 2018
**Based on a retrospective longitudinal study of more than 2,000 cancer cases. Fernandez, G., Prastawa, M., Madduri, A.S. et al. Breast Cancer Research 2022’.
***Paik, New England Journal of Medicine, 2004
The current standard
While gene expression testing adds significantly to the information provided by tumor grading, it can take up to six weeks to complete and costs more than $4,000. And because it’s used primarily with excisional specimens, it requires significant time and labor of the pathology department. Even then, gene expression testing may still rely on subjective tumor grading in its risk score, and the limited reporting features can lead to clinical ambiguity.
See More
Our Solution
Our study of more than 2,000 breast cancer cases* identified 7 morphologic factors that can be visualized in pathology slides and 4 clinical features which, combined in our proprietary algorithm, best predict recurrence at 6 years. Together, the Morphology Feature Array® produces a single Risk Score between 0 and 100 that accurately and consistently stratifies patients into cohorts of low and high risk of tumor recurrence.
PreciseBreast powers the process of diagnosis and cancer care planning for everyone.
Medical society partners
We are proud to work with some of the most important cancer associations and societies.
.png)
Please fill out the form below.
